Takeda Pharmaceutical
TAK
18.37
+0.27
+1.49%
Takeda Pharmaceutical
US · TAK
#400 by market cap
Listed 1970
18.37
+0.27
+1.49%
Live - 5344 symbols - heartbeat 498s ago
· 2026-10-08 07:37
Pre-market
18.37
0.00%
After-hours
18.37
0.00%
Overnight
18.34
-0.16%
- Market cap
- 58.68B
- P/E (TTM)i
- -55.67
- P/Bi
- 1.23
- EPSi
- -0.31
- Div yieldi
- 3.26%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on TAK?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/1/30
-
Společnosti Sceye a SoftBank Corp. Dokončily V Japonsku Demonstraci Stratosférického Připojení a Posunuly Se Tak Směrem Ke Komercializaci Systému HAPSPR Newswire · 2026/9/2
-
Rating change
TR | OpenAI - 4o Initiates Takeda Pharmaceutical(TAK.US) With Hold Rating, Announces Target Price $15.5Market Newswire · 2025/8/11
-
Roadshow (00062.HK) and Sun Hung Kai Properties (00016.HK) have jointly submitted a bid for the Kai Tak Smart Green Mass Transit System.AASTOCKS · 2026/8/17
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $37.37Market Newswire · 2026/7/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $21Market Newswire · 2026/3/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/6/4
-
Company notice
HCK: Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - DATO' DIONG TAK CHONG @ TIONG TAK CHONGBursa Malaysia · 2026/6/29
-
Company notice
OCEAN STAR TECH: PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING (THE "AGM")TO BE HELD AT 10:30 A.M. ON MONDAY, 28 SEPTEMBER 2026 AT ROOM 1606D&E, 16/F., KAI TAK COMMERCIALBUILDING, 317-319 DES VOEUX ROAD CENTRAL, SHEUNG WAN, HONG KONG (OR ANY ADJOURNMENT THEREOF)HKEX · 2026/9/4
-
Company notice
World: Narumiya International accelerates its expansion in the Hong Kong market, with its kids' brand "petit main" opening consecutively at Sogo Causeway Bay and Kai Tak stores.JPX · 2026/5/25
-
[New Launch] LOHAS Park’s Kai Tak Bay series has sold over 1,150 units, generating proceeds exceeding HK$10 billion.AASTOCKS · 2026/9/15
-
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $44.21Market Newswire · 2026/9/15
-
Company notice
Takeda Pharmaceutical: U.S. FDA Accepts NDA and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepy Type 1JPX · 2026/2/10
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $16Market Newswire · 2025/5/21
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $37.47Market Newswire · 2025/3/10
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $42.65Market Newswire · 2026/8/13
-
Company notice
KING INTL INV: Form of proxy for the Annual General Meeting to be held at 12:00 p.m., Room 3302, 33/F, West Tower, Shun Tak Centre, 200 Connaught Road Central, HongKong on Friday, 4 September 2026.HKEX · 2026/7/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2025/9/9
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy RatingMarket Newswire · 2026/8/7
-
[Hong Kong Property] A four-bedroom unit at The Crown Kai Tak was sold for HK$169 million, translating to a price of HK$79,073 per square foot, setting new records for both transaction price and unit price among standard layouts.AASTOCKS · 2026/9/21
-
[New Launch] Kai Tak Bay to Offer 100 Units via Price List on Saturday, with Net Selling Prices Starting at HK$5.6 MillionAASTOCKS · 9/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 07:37:49 · For reference only, not investment advice and not tailored to your situation.